Response to "Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?"

Affiliations

¹ Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. wdenbrok@bccancer.bc.ca.
² Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
³ Department of Radiation Oncology, BC Cancer Agency, Vancouver, BC, Canada.

Comment

Wendie D den Brok et al. Breast Cancer Res Treat. 2017 Apr.

. 2017 Apr;162(2):397-398.

doi: 10.1007/s10549-017-4114-y.

¹ Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada. wdenbrok@bccancer.bc.ca.
² Department of Medical Oncology, BC Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6, Canada.
³ Department of Radiation Oncology, BC Cancer Agency, Vancouver, BC, Canada.

No abstract available

Comment on

Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA. den Brok WD, et al. Breast Cancer Res Treat. 2017 Feb;161(3):549-556. doi: 10.1007/s10549-016-4080-9. Epub 2016 Dec 20. Breast Cancer Res Treat. 2017. PMID: 28000014
Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?
Altundag K. Altundag K. Breast Cancer Res Treat. 2017 Apr;162(2):395-396. doi: 10.1007/s10549-017-4109-8. Epub 2017 Jan 16. Breast Cancer Res Treat. 2017. PMID: 28091861 No abstract available.